文献速递胸部肿瘤

意大利晚期非鳞状肺癌患者一线帕博利珠单抗联合铂类-培美曲塞治疗的真实世界结局

Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
PubMed 文献 · Eur J Cancer · 2024-03-11

这项多中心、回顾性/前瞻性队列观察研究在33个意大利中心评估了晚期非鳞状非小细胞肺癌患者一线化疗-免疫治疗(顺铂/卡铂、培美曲塞和帕博利珠单抗)的常规临床实践结局。截至2023年1月31日共纳入1068例患者,中位随访17.0个月后中位总生存期为16.1个月,中位无进展生存期为9.9个月,客观缓解率为43.4%。作者认为该方案在这项大型真实世界意大利研究中有效且可耐受,结果与KEYNOTE-189注册研究一致。

要点

  • 中位随访17.0个月,中位OS为16.1个月,中位PFS为9.9个月。
  • 客观缓解率为43.4%,中位缓解持续时间(n=493)为14.7个月。
  • 任何级别不良事件发生率为59.6%,≥3级不良事件发生率为23.7%。

核心结论

  • 作者认为,在这项大型真实世界意大利研究中,一线化疗-免疫治疗对晚期非鳞状非小细胞肺癌患者有效且可耐受,结果与KEYNOTE-189注册研究一致,也考虑到本研究中PD-L1≥50%患者数量较少。

研究设计与样本

  • 多中心、回顾性/前瞻性队列观察研究,在33个意大利中心评估常规临床实践中一线顺铂/卡铂、培美曲塞和帕博利珠单抗治疗晚期非鳞状非小细胞肺癌患者。
  • 截至2023年1月31日数据截止时共纳入1068例患者,其中812例(76.0%)属于回顾性队列。
  • 中位年龄为66岁(范围27-85岁),ECOG PS≥2者91例(8.6%),基线有脑转移者254例(23.8%),肿瘤PD-L1表达≥50%者38例(3.6%)。

主要发现

  • 中位随访17.0个月(95% CI,16.1-17.9),中位OS为16.1个月(95% CI,14.4-18.8),中位PFS为9.9个月(95% CI,8.8-11.2)。
  • 中位DoR(n=493)为14.7个月(95% CI,13.6-17.1),ORR为43.4%(95% CI,40.4-46.4)。
  • 任何级别AE发生于636例(59.6%)患者,≥3级AE发生于253例(23.7%)患者;最常见的≥3级AE为中性粒细胞减少(6.3%)和贫血(6.3%)。

关键数值与推荐

  • 中位OS为16.1个月(95% CI,14.4-18.8),中位PFS为9.9个月(95% CI,8.8-11.2)。
  • ORR为43.4%(95% CI,40.4-46.4),中位DoR(n=493)为14.7个月(95% CI,13.6-17.1)。
  • 任何级别AE发生率为59.6%,≥3级AE发生率为23.7%;最常见的≥3级AE为中性粒细胞减少(6.3%)和贫血(6.3%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this multi-center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first-line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in 33 Italian centers. METHODS: The outcome measure was to evaluate overall survival (OS) in a real-world patient population. Secondary endpoints were: progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) and incidence of treatment-related adverse events (AEs). RESULTS: 1068 patients were enrolled at the time of data cut-off (January 31st, 2023), and 812 (76.0%) belonged to the retrospective cohort. Median age was 66 years (27-85), ECOG PS was ≥ 2 in 91 (8.6%) patients; 254 (23.8%) patients had brain metastases at baseline; 38 (3.6%) patients had tumor with PD-L1 expression ≥ 50%. After a median follow-up of 17.0 months (95% CI, 16.1-17.9), median OS was 16.1 months (95% CI, 14.4-18.8) and PFS was 9.9 months (95% CI, 8.8-11.2). Median DoR (n = 493) was 14.7 months (95% CI, 13.6-17.1). ORR was 43.4% (95% CI, 40.4-46.4). Any-grade AEs occurred in 636 (59.6%) patients and grade ≥ 3 in 253 (23.7%) patients. Most common grade ≥ 3 AEs were neutropenia (6.3%) and anemia (6.3%). CONCLUSIONS: First-line chemo-immunotherapy was effective and tolerable in this large, real-world Italian study of patients with advanced non-squamous NSCLC. Our results were in line with the KEYNOTE-189 registration study, also considering the low number of PD-L1 ≥ 50% patients included in our study.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Leonetti A, Perrone F, Puntoni M, et al. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed. Eur J Cancer. 2024. PMID: 38489861. doi:10.1016/j.ejca.2024.114006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。